Temporal control of tumor growth in nocturnal mammals: impact of the circadian system
P. M. Wagner, C. Prucca, F. Velazquez, L. Sosa Alderete, B. L. Caputto, M. E. GUIDO
Abstract
Glioblastoma multiforme is the most aggressive brain tumor; however, little is known about the impact of the circadian system on the tumor formation, growth and treatment. We investigated day/night differences in tumor growth after injecting A530 glioma cells isolated from malignant peripheral nerve sheath tumor of NPcis (Trp53+/-; Nf1+/-) mice. Tumors generated in the sciatic nerve zone of C57BL/6 mice injected early at night in the light/dark cycle or in constant darkness, showed higher growth rates than in animals injected diurnally. Similar nocturnal increases were observed when injecting B16 melanoma cells or when mice received knocked-down clock gene Bmal1 cells. Moreover, treatment with a low-dose of the proteasome inhibitor Bortezomib (0.5 mg/kg) in tumor-bearing animals, displayed higher efficacy when administered at night. Results suggest the existence of a precise temporal control of tumor growth and of drug efficacy in which the host state and susceptibility are critical.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host
Maria F. Gonzalez-Aponte, Anna R. Damato, … Erik D. Herzog·Cancer CellPeer-reviewed·Dec 12, 2024
- Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma
M. F. Gonzalez-Aponte, A. R. Damato, … E. D. Herzog·bioRxiv·Sep 13, 2023
- Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology
P. M. Wagner, M. E. Guido·bioRxiv·Nov 23, 2023
- Nobiletin Affects Circadian Rhythms and Oncogenic Characteristics in a Cell-Dependent Manner
S. S. Lellupitiyage Don, K. L. Robertson, … M. E. Farkas·bioRxiv·Jan 14, 2020
- Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials
Priscilla Chan, Yoshiko Nagai, … Steve A. Kay·Neuro-OncologyPeer-reviewed·Apr 1, 2025
- Differential roles of pyramidal and fast-spiking, GABAergic neurons in the control of glioma cell proliferation
E. Tantillo, E. Vannini, … M. Caleo·bioRxiv·Mar 5, 2020